Ocuphire Pharma Inc
Research Ocuphire Pharma Inc (IRD) on Bullrun: market cap USD 339.68M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIRD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 339.68M
- Financial periodQ2 2026
- RevenueUSD 755.00K
- Net income-USD 8.10M
- Free cash flow-USD 11.95M
Valuation Snapshot
latest market cap is USD 339.68M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 14.20M | -USD 49.59M | -USD 35.25M | n/a | -0.8 | USD 45.09M | USD 1.13M | USD 15.35M |
| FY2024 | USD 10.99M | -USD 57.53M | -USD 25.58M | n/a | -2.15 | USD 30.32M | USD 0 | USD 6.72M |
| FY2023 | USD 19.05M | -USD 9.99M | n/a | n/a | -0.46 | USD 50.50M | n/a | USD 49.91M |
| FY2022 | USD 39.85M | USD 17.89M | n/a | n/a | 0.87 | USD 42.63M | USD 0 | USD 46.24M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 339.68M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 140.49M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 37.57M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 68.14M | 2.3 | n/a | n/a |
| 2022 | 2022-12-30 | USD 73.45M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 70.29M | n/a | n/a | n/a |
About Ocuphire Pharma Inc
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ocuphire Pharma Inc's market cap?
Ocuphire Pharma Inc's market capitalization is USD 339.68M.
What does Ocuphire Pharma Inc do?
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.